TY - GEN
T1 - Fluorescently labeled bevacizumab in human breast cancer
T2 - Clinical and Preclinical Optical Diagnostics 2017
AU - Koch, Maximilian
AU - De Jong, Johannes S.
AU - Glatz, Jürgen
AU - Symvoulidis, Panagiotis
AU - Lamberts, Laetitia E.
AU - Adams, Arthur L.L.
AU - Kranendonk, Mariëtte E.G.
AU - Terwisscha Van Scheltinga, Anton G.T.
AU - Aichler, Michaela
AU - Jansen, Liesbeth
AU - De Vries, Jakob
AU - Lub-De Hooge, Marjolijn N.
AU - Schröder, Carolien P.
AU - Jorritsma-Smit, Annelies
AU - Linssen, Matthijs D.
AU - De Boer, Esther
AU - Van Der Vegt, Bert
AU - Nagengast, Wouter B.
AU - Elias, Sjoerd G.
AU - Oliveira, Sabrina
AU - Witkamp, Arjen J.
AU - Mali, Willem P.Th M.
AU - Van Der Wall, Elsken
AU - Garcia-Allende, P. Beatriz
AU - Van Diest, Paul J.
AU - De Vries, Elisabeth G.E.
AU - Walch, Axel
AU - Van Dam, Gooitzen M.
AU - Ntziachristos, Vasilis
N1 - Publisher Copyright:
© COPYRIGHT SPIE. Downloading of the abstract is permitted for personal use only.
PY - 2017
Y1 - 2017
N2 - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
AB - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
UR - http://www.scopus.com/inward/record.url?scp=85033566002&partnerID=8YFLogxK
U2 - 10.1117/12.2286062
DO - 10.1117/12.2286062
M3 - Conference contribution
AN - SCOPUS:85033566002
T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE
BT - Clinical and Preclinical Optical Diagnostics
A2 - Brown, J. Quincy
A2 - van Leeuwen, Ton G.
PB - SPIE
Y2 - 25 June 2017 through 27 June 2017
ER -